Board of Directors

The founding mission of AltraTech Ltd is to offer people the biological insights they need to live the healthiest lives they can, with a new class of accessible molecular diagnostic technology.  Our multidisciplinary team has over 100 years of experience in semiconductors, genetics, microfluidics, chemistry, and life-science product commercialization:


Tara Dalton,  Ph.D,  CEO
Tara holds eight US patents in microfluidic droplet processing, for DNA/genome extraction and analysis. Her most recent peer-reviewed publications focus on RNA gene expression profiling of colorectal cancers at University Hospital Limerick. In 2007 she founded and spun-out Stokes-Bio from University of Limerick, focusing on high-throughput sample extraction and PCR analysis.  Stokes-Bio was acquired by Life Technologies Inc in 2010.

Tim Cummins, CTO  & Co-Founder
Tim has 25 years’ experience in semiconductors and sensors, in design, business development, sales, and senior management.  Previously he was Sensors Product Line Director in Silicon Laboratories Inc, following its acquisition of his startup environmental sensor company ChipSensors.    He has 5 IEEE publications (incl 2 invited journal papers), and holds 18 US patents, all successfully commercialised.

Brian O’Farrell, Ph.D, CSO & Co-Founder
Brian has 15 years’ experience in molecular biology, population genetics, and lab-on-chip biotechnology.  In AltraTech he has invented a novel enzyme-free genotyping platform. Previously, in ERI he designed, built, and commissioned a robotic pipeline for high-volume microbial genotyping of Salmonella and E.Coli bacterial strains.  Proficient in Python and SQL, he has 6 publications on sample-preparation and bioinformatics.

Gerard Insley, Ph.D, CRO
Gerard oversees our regulatory affairs and compliance matters.  He has over 20 years of experience in  these areas, and has developed and successfully commercialised many in-vivo products to ISO13485 CE & FDA510k certification. He was previously Director of R&D Biomaterials & Operations at Stryker Orthobiologics, and is a co-founder of  CelGenTek, a startup orthobiologics company, acquired by Zimmer-Biomet in 2016.

Ron Opstelten, Ph.D, Business Development Dir
Ron has over 25 years’ experience in BioTechnology and Molecular Diagnostics, in Director and VP global sales roles roles, in Qiagen, Sigma-Aldrich, and Abbott Diagnostics.  He has a record of success in sales, marketing, business development,  molecular biological manufacturing processes and customer operations.